Navigation Links
Inovio Pharmaceuticals CEO Receives 2013 Drug Discovery & Achievement Award
Date:11/13/2013

erating best-in-class immune responses, with therapeutic T-cell responses exceeding other technologies in terms of magnitude, breadth, and response rate. Human data to date have shown a favorable safety profile. Inovio's lead vaccine, a therapeutic against HPV-caused pre-cancers and cancers, is in phase II. Other phase I and preclinical programs target prostate, breast, and lung cancers as well as HIV, influenza, malaria and hepatitis. Partners and collaborators include Roche, the University of Pennsylvania, Merck, NIH, HIV Vaccines Trial Network, National Cancer Institute, U.S. Military HIV Research Program, University of Southampton, US Dept. of Homeland Security, University of Manitoba and PATH Malaria Vaccine Initiative. More information is available at www.inovio.com.

This press release contains certain forward-looking statements relating to our business, including our plans to develop electroporation-based drug and gene delivery technologies and DNA vaccines and our capital resources. Actual events or results may differ from the expectations set forth herein as a result of a number of factors, including uncertainties inherent in pre-clinical studies, clinical trials and product development programs (including, but not limited to, the fact that pre-clinical and clinical results referenced in this release may not be indicative of results achievable in other trials or for other indications, that the studies or trials may not be successful or achieve the results desired, that pre-clinical studies and clinical trials may not commence or be completed in the time periods anticipated, that results from one study may not necessarily be reflected or supported by the results of other similar studies and that results from an animal study may not be indicative of results achievable in human studies), the availability of funding to support continuing research and studies in an effort to prove safety and efficacy of electroporat
'/>"/>

SOURCE Inovio Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology news :

1. MVI and Inovio partner to develop malaria vaccines using innovative vaccine delivery tech
2. Scripps Research announces research & license agreement with Janssen Pharmaceuticals
3. Scripps Research and Takeda Pharmaceuticals announce expanded research collaboration
4. Sanford-Burnham and 60° Pharmaceuticals to pursue promising target for the treatment of dengue fever
5. Combination of two pharmaceuticals proves effective in the treatment of multiple sclerosis
6. Conatus Pharmaceuticals Appoints Mark F. Morris as Head of Biostatistics
7. AcelRx Pharmaceuticals Receives First U.S. Patent for Small-Volume Oral Transmucosal Dosage Forms
8. Fish show autism-like gene expression in water with psychoactive pharmaceuticals
9. Tokai Pharmaceuticals galeterone well-tolerated in patients with advanced prostate cancer
10. From scourge to saint: E. coli bacteria becomes a factory - to make cheaper, faster pharmaceuticals
11. Sanford-Burnham receives US Air Force grant to perform next-generation toxicity screens
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/6/2015)... Conn. , Apr. 6, 2015 NXT-ID, ... "Company"), a biometric authentication company focused on the ... has filed provisional patent 62/143028 for ... COMMUNICATIONS AND ENERGY TRANSFER  NXT-ID introduces a ... payments. This patent surrounds the use of miniature ...
(Date:4/1/2015)... Conn. , Apr. 1, 2015  NXT-ID, Inc. ... biometric authentication company focused on the growing mobile commerce ... of Wocket smart wallets is underway to early access ... access group includes usage at retail outlets including Walmart, ... Pharmacy. Users report Wocket was accepted at all outlets ...
(Date:3/26/2015)... 26, 2015 The Granite Club, ... and athletic club, today announced it has implemented a ... of movement for members and staff, while restricting access ... process, we selected FST,s IMID Access system because it ... our members and staff, in addition to unparalleled security," ...
Breaking Biology News(10 mins):NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 2NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 3NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 4NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 2NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 3NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 4Granite Club First Private Club in North America to Implement FST Biometrics Secure Access Solution, as Part of Multi-million Dollar Expansion 2
... has published a paper today that is the most ... temperatures are having on the worlds coral reefs. ... Change and Ocean Acidification, co-authored by seventeen marine scientists ... will not survive the drastic increases in global temperatures ...
... Mass. -- A pioneering study of wild chimpanzees has ... experience menopause, rebutting previous studies of captive individuals which ... 35 to 40 years of age. Together with ... -- described this week in the journal Current Biology ...
... the Open Access publisher for Physics, Mathematics and ... CERN and DESY high-energy physics laboratories. Under ... charges for all research published by their investigators ... A. PMC Physics A is edited by ...
Cached Biology News:Immediate action needed to save corals from climate change 2Immediate action needed to save corals from climate change 3Wild chimpanzees appear not to regularly experience menopause 2Top physics laboratories sign up to open access with PhysMath Central 2
(Date:4/23/2015)... 23, 2015  Neurocrine Biosciences, Inc. (Nasdaq: NBIX ... first quarter 2015 results before the Nasdaq market opens ... a live conference call and webcast to discuss its financial ... 30, 2015 at 8:00 a.m. Eastern Time (5:00 a.m. ... conference call by dialing 866-952-1906 (US) or 785-424-1825 (International) ...
(Date:4/23/2015)... , April 23, 2015  Cryoport, Inc. (OTCBB: ... logistics solutions for the life sciences industry, today ... cryogenic logistics solutions within the animal husbandry market ... Farms to support the shipment of equine semen ... horse Stallions. Animal husbandry is ...
(Date:4/23/2015)... Bethlehem, PA (PRWEB) April 23, 2015 ... announce it is the first EMC® Enterprise Content ... on the entire EMC Documentum® for Life ... Glemser has proven knowledge and capabilities to provide ... Documentum-based, purpose-built solutions. , The EMC Documentum ...
(Date:4/23/2015)... NEW YORK , April 23, 2015 /PRNewswire/ ... development stage healthcare company, focuses on the development ... colorectal cancer. The company lead product includes PRP, ... as trypsinogen and chymotrypsinogen, as well as the ... It is also developing a combination of anti-cancer ...
Breaking Biology Technology:Neurocrine Biosciences Announces Conference Call and Webcast to Report First Quarter 2015 Results 2Cryoport to Support the Equine Animal Husbandry Market Through Agreement with Yancey Farms 2Cryoport to Support the Equine Animal Husbandry Market Through Agreement with Yancey Farms 3Glemser Earns Accreditation for Life Sciences Solution Suite 2Early Stage BioTech offers Plenty of Risk; Propanc Health Group Analyst Brief Issued by BrokerBank Securities, Inc. 2
... April 25 /Xinhua-PRNewswire-FirstCall/ -- China Yingxia,International, Inc. ... "the,Company"), a leading provider in the nutraceutical ... of organic nutritional food,products, supplements, and personal ... ("PRC"), today announced that it has formally ...
... WESTBROOK, Maine, April 25 IDEXX,Laboratories, Inc. (Nasdaq: ... of 2008 increased 18% to $249.1 million from $211.2 ... share ("EPS") for the,quarter ended March 31, 2008 were ... prior year. Non-GAAP adjusted diluted EPS for the first,quarter ...
... Therapeutics,Inc. (Nasdaq: CVTX ) today reported financial results for ... ended March 31, 2008, the Company reported a net loss,of ... net loss of $34.1,million, or $0.57 per share, for the ... per share, for the same quarter in 2007., For ...
Cached Biology Technology:China Yingxia International, Inc. Acquires Grocery Chain and Online Distribution Network 2China Yingxia International, Inc. Acquires Grocery Chain and Online Distribution Network 3IDEXX Laboratories Announces First Quarter Results 2IDEXX Laboratories Announces First Quarter Results 3IDEXX Laboratories Announces First Quarter Results 4IDEXX Laboratories Announces First Quarter Results 5IDEXX Laboratories Announces First Quarter Results 6IDEXX Laboratories Announces First Quarter Results 7IDEXX Laboratories Announces First Quarter Results 8IDEXX Laboratories Announces First Quarter Results 9IDEXX Laboratories Announces First Quarter Results 10IDEXX Laboratories Announces First Quarter Results 11IDEXX Laboratories Announces First Quarter Results 12IDEXX Laboratories Announces First Quarter Results 13IDEXX Laboratories Announces First Quarter Results 14IDEXX Laboratories Announces First Quarter Results 15IDEXX Laboratories Announces First Quarter Results 16IDEXX Laboratories Announces First Quarter Results 17CV Therapeutics Reports 2008 First Quarter Financial Results 2CV Therapeutics Reports 2008 First Quarter Financial Results 3CV Therapeutics Reports 2008 First Quarter Financial Results 4CV Therapeutics Reports 2008 First Quarter Financial Results 5
... 100% capped transcripts with the translation boosting ... of 100% capped (versus 40% to 80% ... in about 2 hours. mScript™ also features ... shown to be up to 50% more ...
... with Gateway™ Technology is designed to ... polyhedrin promoter. The expression cassette is ... DNA) by site-specific transposition (Tn7) in ... bacmid DNA is then used for ...
Immunogen: Synthetic peptide: M(1) C V P R S G L I L S(11) Storage: -20 C, Avoid Freeze/Thaw Cycles...
Request Info...
Biology Products: